• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Oba Takaaki  大場 崇旦

ORCIDConnect your ORCID iD *help
Researcher Number 90724906
Other IDs
Affiliation (Current) 2026: 信州大学, 学術研究院医学系(医学部附属病院), 講師
Affiliation (based on the past Project Information) *help 2024: 信州大学, 学術研究院医学系(医学部附属病院), 講師
2023: 信州大学, 学術研究院医学系(医学部附属病院), 助教
2022: 信州大学, 学術研究院医学系, 助教
2021: 信州大学, 医学部附属病院, 助教(診療)
Review Section/Research Field
Principal Investigator
Basic Section 50010:Tumor biology-related
Keywords
Principal Investigator
疲弊前駆T細胞 / 乳癌 / センチネルリンパ節 / 腫瘍内注入療法 / 免疫療法 / 抗PD-L1治療 / エピジェネティック治療 / トリプルネガティブ乳癌 / エピジェネティック治療薬 / 免疫細胞 / エリブリン
  • Research Projects

    (2 results)
  • Research Products

    (7 results)
  •  Development of novel therapeutic strategy for breast cancer using sentinel lymph node through the analysis of difference in immune response between sentinel and non-sentinel lymph nodePrincipal Investigator

    • Principal Investigator
      大場 崇旦
    • Project Period (FY)
      2024 – 2026
    • Research Category
      Grant-in-Aid for Early-Career Scientists
    • Review Section
      Basic Section 50010:Tumor biology-related
    • Research Institution
      Shinshu University
  •  Development of Immunotherapy for Triple-Negative Breast Cancer Using Local Epigenetic TherapyPrincipal Investigator

    • Principal Investigator
      Oba Takaaki
    • Project Period (FY)
      2021 – 2023
    • Research Category
      Grant-in-Aid for Early-Career Scientists
    • Review Section
      Basic Section 50010:Tumor biology-related
    • Research Institution
      Shinshu University

All 2023 2022 2021

All Journal Article Presentation

  • [Journal Article] Eribulin promotes proliferation of CD8+ T cells and potentiates T cell-mediated anti-tumor activity against triple-negative breast cancer cells2023

    • Author(s)
      Shimizu Tadafumi、Oba Takaaki、Oshi Masanori、Ito Ken-ichi
    • Journal Title

      Breast Cancer Research and Treatment

      Volume: 203 Issue: 1 Pages: 57-71

    • DOI

      10.1007/s10549-023-07111-x

    • Peer Reviewed
    • Data Source
      KAKENHI-PROJECT-21K15529
  • [Presentation] Eribulinがトリプルネガティブ乳癌に対する腫瘍免疫に及ぼす効果の解析2023

    • Author(s)
      清水忠史、大場崇旦
    • Organizer
      第31回日本乳癌学会学術総会
    • Data Source
      KAKENHI-PROJECT-21K15529
  • [Presentation] Analysis of the effect of Eribulin on tumor immunity against triple negative breast cancer2023

    • Author(s)
      清水忠史、大場崇旦
    • Organizer
      第82回日本癌学会学術総会
    • Data Source
      KAKENHI-PROJECT-21K15529
  • [Presentation] Analysis of the effect of eribulin on tumor immunity against triple-negative breast cancer2023

    • Author(s)
      Tadafumi Shimizu, Takaaki Oba
    • Organizer
      AACR ANNUAL MEETING 2024
    • Int'l Joint Research
    • Data Source
      KAKENHI-PROJECT-21K15529
  • [Presentation] Analysis of the effect of Eribulin on tumor immunity against triple negative breast cancer2022

    • Author(s)
      清水忠史、大場崇旦
    • Organizer
      第81回日本癌学会学術総会
    • Data Source
      KAKENHI-PROJECT-21K15529
  • [Presentation] Analysis of the effect of Eribulin on tumor immunity against triple negative breast cancer2022

    • Author(s)
      清水忠史、大場崇旦
    • Organizer
      第30回日本乳癌学会学術総会
    • Data Source
      KAKENHI-PROJECT-21K15529
  • [Presentation] Analysis of the effect of Eribulin on tumor immunity against triple negative breast cancer2021

    • Author(s)
      清水忠史、大場崇旦
    • Organizer
      第80回日本癌学会学術総会
    • Data Source
      KAKENHI-PROJECT-21K15529

URL: 

Are you sure that you want to link your ORCID iD to your KAKEN Researcher profile?
* This action can be performed only by the researcher himself/herself who is listed on the KAKEN Researcher’s page. Are you sure that this KAKEN Researcher’s page is your page?

この研究者とORCID iDの連携を行いますか?
※ この処理は、研究者本人だけが実行できます。

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi